Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
MTPConnect set to back startups in heart disease and diabetes
MTPConnect will inject some much-needed funding for Australian SMEs to commercialise innovative...
Qld launches science strategy to support economic growth
The Future Queensland Science Strategy 2024–2029 is set to put the state on a new...
Govt expands funding for a diverse STEM workforce
As the search begins for Australia's next Superstars of STEM, the federal government has...
